Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.
Levesque, S., St-Denis, Y., Bachand, B., Preville, P., Leblond, L., Winocour, P.D., Edmunds, J.J., Rubin, J.R., Siddiqui, M.A.(2001) Bioorg Med Chem Lett 11: 3161-3164
- PubMed: 11720865 
- DOI: https://doi.org/10.1016/s0960-894x(01)00661-8
- Primary Citation of Related Structures:  
1JWT - PubMed Abstract: 
Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the P1 residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo.
Organizational Affiliation: 
Shire BioChem Inc., 275 Armand-Frappier Blvd., Laval, H7V 4A7, Québec, Canada. slevesque@ca.shire.com